Trigeminal Schwannoma: A Retrospective Analysis of Endoscopic Endonasal Management, Treatment Outcomes, and Neuropathic Sequelae

三叉神经鞘瘤:内镜经鼻治疗、治疗结果及神经病变后遗症的回顾性分析

阅读:1

Abstract

Introduction  Trigeminal schwannomas (TS) are rare skull base tumors that have been associated with significant neuropathic sequalae for patients. The authors aim to evaluate the clinical features, treatment outcomes, and neuropathic sequelae following endoscopic endonasal approach (EEA) for TS. Methods  The study involves a retrospective review of patients who underwent EEA for resection of TS at a single academic institution between 2004 and 2020. Radiographic and clinical data were recorded and analyzed. Results  A total of 16 patients were abstracted, with a mean age at the time of surgery of 44 years with a slight female (1.83:1) predominance. Primary preoperative symptomatology included facial pain/neuralgia ( n  = 5, 31.3%), facial hypoesthesia ( n  = 4, 25.0%), and headache ( n  = 4, 25.0%). Following TS resection, patients were found to have facial hypoesthesia ( n  = 11, 68.8%), neuropathic keratopathy ( n  = 4, 25.0%), and mastication musculature atrophy ( n  = 3, 18.8%). Patients with preoperative facial pain/neuralgia ( n  = 5, 31.3%) were significantly more likely to try adjunctive pain therapies ( p  = 0.018) as well as seek pain consultation ( p  = 0.018). Patients with preoperative migraines ( n  = 2, 12.5%) were significantly more likely to trial adjunctive pain therapies ( p  = 0.025) and undergo evaluation with pain specialists ( p  = 0.025). Finally, patients with preoperative pharmacologic agent utilization were significantly more likely to trial adjunctive pain therapies ( p  = 0.036) and pursue pain consultation ( p = 0.036). Conclusion  Some degree of trigeminal dysfunction may be more common than previously reported following EEA for TS resection. Factors that appear to play a role in the development of trigeminal dysfunction include pre-existing pain syndromes such as facial pain/neuralgia or headache and preoperative medication utilization.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。